Investing.com - Biondvax Pharma ADR reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Biondvax Pharma ADR announced earnings per share of $0.003 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.100 on revenue of $0.00.
Biondvax Pharma ADR shares are down 61.11% from the beginning of the year and are trading at $9.140 , down-from-52-week-high.
Biondvax Pharma ADR shares lost 2.35% in intra-day trade the report.
Biondvax Pharma ADR follows other major Healthcare sector earnings this month
Biondvax Pharma ADR's report follows an earnings beat by Eli Lilly on November 1, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
Novo Nordisk ADR had beat expectations on November 2 with third quarter EPS of $0.8409 on revenue of $6.04B, compared to forecast for EPS of $0.837 on revenue of $6.04B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar